Kaposi sarcoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:33276OMIM:148000C46.0C46.1C46.2
Who is this for?
Show terms as
1FDA treatments12Active trials57Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Kaposi sarcoma (KS) is a type of cancer that causes abnormal growths in the skin, lymph nodes, and internal organs. It develops from the cells that line blood vessels and lymph vessels. The disease is closely linked to infection with a virus called Human Herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV). KS appears in several forms depending on who it affects: classic KS (mainly in older men of Mediterranean or Eastern European descent), endemic KS (in sub-Saharan Africa), epidemic or AIDS-related KS (in people with HIV/AIDS), and iatrogenic KS (in people taking immune-suppressing medications after organ transplants). The most visible sign of Kaposi sarcoma is skin lesions — flat or raised patches that are often red, purple, brown, or pink. These can appear anywhere on the body, including the face, legs, and mouth. The disease can also affect the lungs, digestive tract, and lymph nodes, causing more serious symptoms like breathing problems, swallowing difficulties, or swelling in the legs. Treatment depends on the type of KS and how widespread it is. For HIV-related KS, starting antiretroviral therapy (ART) to control HIV is often the first and most important step. Other treatments include chemotherapy, radiation therapy, immunotherapy, and targeted therapies. While KS can be managed effectively in many people, it remains a serious condition that requires ongoing medical care.

Key symptoms:

Red, purple, brown, or pink skin patches or bumps (lesions)Swelling in the legs, feet, or face (lymphedema)Painful or uncomfortable skin growthsLesions inside the mouth or throatShortness of breath or coughing (if lungs are affected)Nausea, vomiting, or stomach pain (if digestive tract is affected)Blood in stool or vomitDifficulty swallowingSwollen lymph nodesFatigue and general weaknessWeight lossFever (often related to underlying HIV or infection)

Clinical phenotype terms (26)— hover any for plain English
Recurrent herpesHP:0005353Abnormal retinal morphologyHP:0000479Abnormality of the spleenHP:0001743Lymphoproliferative disorderHP:0005523Generalized lymphadenopathyHP:0008940
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Sep 2026A Study of Propranolol to Treat Kaposi Sarcoma

AIDS Malignancy Consortium — PHASE2

TrialNOT YET RECRUITING
May 2026Precision Imaging to Evaluate Kaposi Sarcoma

Washington University School of Medicine — NA

TrialNOT YET RECRUITING
Aug 2025Propranolol for the Treatment of Kaposi Sarcoma in Adults

Washington University School of Medicine — PHASE2

TrialRECRUITING
Feb 2025Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial

Washington University School of Medicine

TrialRECRUITING
May 2024Natural History Study of Kaposi Sarcoma

National Cancer Institute (NCI)

TrialRECRUITING
Nov 2023Trial of Ixazomib for Kaposi Sarcoma

AIDS Malignancy Consortium — PHASE2

TrialRECRUITING
May 2023Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Imperial College London — PHASE1

TrialACTIVE NOT RECRUITING
Mar 2022Pomalidomide Treatment in Patients With Kaposi Sarcoma

National Cancer Institute (NCI) — PHASE2

TrialACTIVE NOT RECRUITING
Feb 2021Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

National Cancer Institute (NCI) — NA

TrialACTIVE NOT RECRUITING
Sep 2020A Study of sEphB4-HSA in Kaposi Sarcoma

Vasgene Therapeutics, Inc — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

POMALYST�

pomalidomide· Celgene Corporation■ Boxed WarningOrphan Drug
POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of K

POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.

Clinical Trials

12 recruitingView all trials with filters →
Phase 25 trials
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Phase 2
Actively Recruiting
PI: Robert Yarchoan, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Propranolol for the Treatment of Kaposi Sarcoma in Adults
Phase 2
Actively Recruiting
PI: Lee Ratner, M.D., Ph.D. (Washington University School of Medicine) · Sites: St Louis, Missouri · Age: 1899 yrs
A Study of sEphB4-HSA in Kaposi Sarcoma
Phase 2
Actively Recruiting
PI: Carl Millner, M.D. (AIDS Healthcare Foundation) · Sites: Beverly Hills, California; Sarasota, Florida +1 more · Age: 1899 yrs
Pomalidomide Treatment in Patients With Kaposi Sarcoma
Phase 2
Active
PI: Samantha L Vogt (AIDS Malignancy Consortium) · Sites: La Jolla, California; Miami, Florida +13 more · Age: 1899 yrs
Trial of Ixazomib for Kaposi Sarcoma
Phase 2
Actively Recruiting
PI: Erin Reid, MD (AIDS Malignancy Consortium) · Sites: San Diego, California; San Francisco, California +9 more · Age: 1899 yrs
Phase 12 trials
Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma
Phase 1
Active
· Sites: London · Age: 1899 yrs
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Phase 1
Active
PI: Ramya M Ramaswami, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 18120 yrs
N/A2 trials
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
N/A
Active
PI: Ramya M Ramaswami, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
N/A
Actively Recruiting
PI: Robert Yarchoan, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Other2 trials
Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial
Actively Recruiting
PI: Lee Ratner, M.D., Ph.D. (Washington University School of Medicine) · Sites: St Louis, Missouri · Age: 1899 yrs
Natural History Study of Kaposi Sarcoma
Actively Recruiting
PI: Ramya M Ramaswami, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 18120 yrs

Specialists

Showing 25 of 57View all specialists →
EM
Erin Reid, MD
Specialist
PI on 1 active trial
SV
Samantha L Vogt
Specialist
PI on 1 active trial
DP
Dongkyun Kang, PhD
Specialist
PI on 1 active trial
BD
Blossom Damania
Specialist
4 Kaposi sarcoma publications
MM
Malgorzata Mikulska
Specialist
2 Kaposi sarcoma publications
HW
Hao-Wei Wang
BETHESDA, MD
Specialist
2 Kaposi sarcoma publications
JL
Justin Landis
Specialist
2 Kaposi sarcoma publications
AM
Alessandra Mularoni
KENTWOOD, MI
Specialist
2 Kaposi sarcoma publications
DD
Dirk P Dittmer
Specialist
5 Kaposi sarcoma publications
PC
Patricio Cano
Specialist
2 Kaposi sarcoma publications
AP
Alice Peng
Specialist
2 Kaposi sarcoma publications
DD
David A Davis
Specialist
2 Kaposi sarcoma publications
TB
Thomas Bettuzzi
Specialist
1 Kaposi sarcoma publication
RY
Robert Yarchoan
BETHESDA, MD
Specialist
6 Kaposi sarcoma publications
RR
Ramya Ramaswami
BETHESDA, MD
Specialist
5 Kaposi sarcoma publications
RP
Roshani Patel
Specialist
1 Kaposi sarcoma publication
RM
Robert Yarchoan, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 13 active trials
RM
Ramya M Ramaswami, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 10 active trials
RP
Robert Maki, MD, PhD
PHILADELPHIA, PA
Specialist
PI on 8 active trials
LM
Lara Dunn, MD
GOLDEN, CO
Specialist
PI on 1 active trial
MM
Mary L. Keohan, MD
NEW YORK, NY
Specialist
PI on 1 active trial
JM
Joseph A Kovacs, M.D.
Specialist
PI on 6 active trials
DD
Dao Wen Wang, Doctor
Specialist
PI on 2 active trials1 Kaposi sarcoma publication
KS
Kelly Shimabukuro
WESTFIELD, NJ
Specialist
PI on 1 active trial2 Kaposi sarcoma publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Kaposi sarcoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Kaposi sarcomaForum →

No community posts yet. Be the first to share your experience with Kaposi sarcoma.

Start the conversation →

Latest news about Kaposi sarcoma

1 articles
Clinical trialUNITERAREApr 5, 2026
New Recruiting Trial: Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Researchers are testing a new drug called CYT107 to help people with HIV who have Kaposi Sarcoma (a type of cancer) and whose immune systems aren't responding w
See all news about Kaposi sarcoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What type of Kaposi sarcoma do I have, and how does that affect my treatment options?,Should I be tested for HIV and HHV-8 if I haven't been already?,Do I need treatment right away, or is watchful waiting appropriate for my situation?,What are the side effects of the recommended treatment, and how can they be managed?,If I have HIV, how will starting or adjusting antiretroviral therapy affect my KS?,How will we know if the treatment is working, and how often will I need follow-up tests?,Are there clinical trials available that I might be eligible for?

Common questions about Kaposi sarcoma

What is Kaposi sarcoma?

Kaposi sarcoma (KS) is a type of cancer that causes abnormal growths in the skin, lymph nodes, and internal organs. It develops from the cells that line blood vessels and lymph vessels. The disease is closely linked to infection with a virus called Human Herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV). KS appears in several forms depending on who it affects: classic KS (mainly in older men of Mediterranean or Eastern European descent), endemic KS (in sub-Saharan Africa), epidemic or AIDS-related KS (in people with HIV/AIDS), and iatrogenic KS (in people taking

How is Kaposi sarcoma inherited?

Kaposi sarcoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Kaposi sarcoma?

Yes — 12 recruiting clinical trials are currently listed for Kaposi sarcoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Kaposi sarcoma?

25 specialists and care centers treating Kaposi sarcoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Kaposi sarcoma?

1 patient support program are currently tracked on UniteRare for Kaposi sarcoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.